Bridget M. Kuehn

Results from a genomic and molecular analysis presented at the 2015 ASCO Annual Meeting and published in Acta Neuropathology indicate that low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.

Adding the immunotherapeutic vaccine, rindopepimut to bevacizumab may help boost survival in patients with a genetic subtype of glioblastoma associated with poor outcomes.

Patients with BRAF-mutant late-stage melanoma derive a lasting overall survival (OS) benefit from treatment with the combination of dabrafenib and trametinib compared with dabrafenib and placebo, according to the final results from the COMBI-d phase III double-blinded trial.